Hartford, CT – In a push to ease healthcare costs in Connecticut, Governor Ned Lamont has introduced a comprehensive plan to lower prescription drug prices across Connecticut.
The said proposal would limit price increases on generic medications, improve access to drug discount programs, and explore the importation of cheaper prescription drugs from Canada.
The plan is designed to target generic drug price caps, which would primarily benefit residents managing chronic conditions such as diabetes and hypertension.
The governor hopes the initiative, labeled the “Connecticut Prescription Drug Affordability Plan,” will gain bipartisan support during the upcoming Connecticut General Assembly legislative session.
Price caps on generic drugs
Under the proposal, price increases for more than 1,000 generic medications would be tied to inflation.
Drug manufacturers exceeding the cap would face penalties enforced by the Connecticut Department of Revenue Services.
Similar generic drug price control policies have seen success in other states. The said policies stabilize prescription drug costs without compromising medication availability or access.
Discount drug card integration
Lamont also proposes expanding the use of prescription drug discount programs like GoodRx and ArrayRx.
Currently, purchases made through the mentioned programs do not count toward patients’ insurance deductibles. The move resulted in higher out-of-pocket healthcare expenses.
The plan would change that and would allow such purchases to reduce out-of-pocket healthcare expenses.
Healthcare advocates praised the change and advocated for its potential to assist patients facing high medical and pharmacy expenses.
In terms of importation of prescription medications from Canada, the proposal also includes actions to increase price competition by allowing Connecticut to import prescription medications from Canada.
The approach is modeled after efforts in other states, including Florida and Colorado, which have pushed for federal approval to access lower-cost foreign medications.
While hurdles with federal regulations may slow implementation, advocates argue that Canadian drug importation could offer long-term savings for the state.
Public and industry reactions
The plan has garnered support from healthcare advocates who see it as a step toward improving prescription drug affordability in Connecticut.
However, representatives of the pharmaceutical industry have warned that such measures could stifle innovation and reduce investment in research for new drug treatments.
Industry leaders argue that price caps on drugs may hinder access to cutting-edge therapies.
Despite industry pushback, Connecticut lawmakers have indicated that drug affordability will be a top priority in 2025.
Many see this plan as an opportunity to curb rising pharmaceutical costs for both urban and rural communities in the state.
The proposal is scheduled for hearings in the coming weeks, and Lamont has urged legislators to act immediately.
